CEDAR KNOLLS, N.J.,
Nov. 8, 2018 /PRNewswire/ -- MYOS
RENS Technology Inc. ("MYOS" or "the Company") (Nasdaq: MYOS), a
biotherapeutics and bionutrition company and the owner of
Fortetropin®, a proprietary bioactive composition
derived from fertilized egg yolk that helps build lean muscle,
announced today that it has signed a distribution agreement with
Miller Veterinary Supply East ("Miller"), which will allow
MYOS to sell its MYOS Canine Muscle Formula ("MYOS
Canine") in more than 6,000 Veterinary hospitals.
Joseph Mannello, Chief Executive
Officer of MYOS, commented, "This agreement is a major achievement
in our commercial strategy for MYOS Canine which will enable
veterinarians at over 6,000 veterinary hospitals throughout the
Eastern U.S. to offer the only all-natural pet health supplement in
the marketplace that has been shown to increase lean muscle mass
and size and improves mobility. Miller's deep-rooted credibility
and trust as the longest-running wholesale distributor of pet
supplies to veterinarians and licensed pet care professionals in
the U.S., makes them the ideal partner for MYOS Canine as we look
to expand our footprint in the growing veterinary supplements
industry."
Clay Cass, Chief Operating
Officer of Miller Veterinary Supply East, stated, "This is an
exciting opportunity for us to increase the depth of our pet
supplement offerings and provide added value to our veterinary
clients. MYOS Canine Muscle Formula is truly revolutionary and is
highly complementary to our current product portfolio. The fact
that MYOS Canine is an all-natural, single-ingredient supplement,
backed by scientific research, makes it an ideal product all
veterinarians should look to offer dog owners."
About Miller Veterinary Supply East
Miller Veterinary
Supply East services the Northeast US providing licensed
veterinarians the equipment, instruments, pet food, pharmaceuticals
and supplies needed to run their practices. Miller's aim is to
professionally represent their Vendor Partners while providing
added value, exemplary service and an unparalleled hands-on
approach. For more information, please visit
https://millerveteast.com.
About MYOS RENS Technology Inc.
MYOS RENS
Technology Inc. (MYOS), "The Muscle Company®", is a
Cedar Knolls, NJ-based
bionutrition company that develops and markets products that
improve muscle health and performance. MYOS is the owner of
Fortetropin®, a fertilized egg yolk-based product
manufactured via a proprietary process to retain and optimize its
biological activity. Fortetropin has been clinically shown to
increase muscle size and lean body mass in conjunction with
resistance training. MYOS believes Fortetropin has the potential to
redefine existing standards of physical health and wellness. For
more information, please visit www.MYOSRENS.com.
Forward-Looking Statements
Any statements in
this release that are not historical facts are forward-looking
statements. Actual results may differ materially from those
projected or implied in any forward-looking statements. Such
statements involve risks and uncertainties, including but not
limited to those relating to product and customer demand, market
acceptance of our products, the ability to create new products
through research and development, the successful results of
strategic initiatives, the successful launch of our products,
including Qurr®, Yolked®, MYOS
Enteral Nutrition Formula, and MYOS Canine Muscle Formula™
products, the success of our research and development, including
the clinical studies described above, the results of the clinical
evaluation of Fortetropin® and its effects, the
ability to enter into new partnership opportunities and the success
of our existing partnerships, the ability to generate the
forecasted revenue stream and cash flow from sales of our products,
the ability to continue increasing our revenue and gross profit
margins, the ability to achieve a sustainable, profitable business,
the effect of economic conditions, the ability to protect our
intellectual property rights, competition from other providers and
products, the continued listing of our securities on the Nasdaq
Stock Market, risks in product development, our ability to raise
capital to fund continuing operations, and other factors discussed
from time to time in our filings with the Securities and
Exchange Commission. We undertake no obligation to update or revise
any forward-looking statement for events or circumstances after
the date on which such statement is made except as required by
law.
Investor Relations:
Porter LeVay & Rose
Michael Porter, President
Phone: 212-564-4700
Email: MYOS@plrinvest.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/myos-rens-technology-signs-distribution-agreement-with-miller-veterinary-supply-east-to-bring-innovative-myos-canine-muscle-formula-to-6-000-veterinary-hospitals-300746031.html
SOURCE MYOS RENS Technology